Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies operating in every region of the globe. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). We have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and Multiple Sclerosis.
Driven by our commitment to patients, we strive to develop strong relationships with patient communities and listen to their perspectives so that we can truly understand their needs. These collaborations guide us as we continue to push the boundaries of medicine and technology to develop new and better therapies that give hope to patients.
Genzyme's Therapeutic Areas
Regardless of disease area or size of the patient community, our approach is to provide personalised care by truly understanding patients’ needs. This special approach is evident across the company and in each of our business units:
Genzyme first began operation in Australia with the opening of our Sydney office in 1994. Since 2011 Genzyme has been part of the Sanofi Group. In Australia and New Zealand, we employ approximately 40 people full time. The Genzyme team covers sales and marketing, medical affairs, finance and administrative support.
The Genzyme business in Australia and New Zealand is focused on rare genetic diseases, Multiple Sclerosis and thyroid cancer. Genzyme Australia and New Zealand is also committed to a number of clinical studies and research and development projects.